DexCom (DXCM) Q2 Revenue Jumps 15%

DexCom reported strong Q2 2025 results, with GAAP revenue of $1.16 billion, up 15% year-over-year and exceeding analyst estimates, alongside beating Non-GAAP EPS expectations at $0.48. This outperformance was driven by robust U.S. and international growth, notably from expanding market access for type 2 diabetes patients and successful new product launches like the FDA-approved G7 15 Day CGM and the Stelo OTC CGM. Despite a non-GAAP gross margin decline to 60.1% due to elevated freight and supply chain costs, management raised full-year FY2025 revenue guidance to $4.60-$4.63 billion, signaling confidence in continued demand and anticipating margin recovery in the second half.

Analysis

DexCom reported a robust second quarter for fiscal 2025, exceeding analyst expectations with GAAP revenue of $1.16 billion, a 15.2% year-over-year increase, and non-GAAP EPS of $0.48. Growth was broad-based with U.S. and international sales rising 15% and 16% respectively, underpinned by a strategic shift towards a more durable business model where recurring sensor revenue now constitutes 97% of total sales. The company is successfully penetrating the large type 2 diabetes market, reporting record new patient starts and securing expanded Pharmacy Benefit Manager (PBM) coverage expected in the second half of 2025. This market expansion is complemented by key product innovation, including the recent FDA approval of the G7 15 Day CGM and growing traction for the Stelo over-the-counter device. However, this strong top-line performance was partially offset by significant margin compression. Non-GAAP gross margin declined 3.4 percentage points to 60.1%, a direct result of elevated freight costs, tariffs, and expedited shipping used to replenish inventory. Despite these cost headwinds, management raised its full-year revenue guidance to a range of $4.60–$4.63 billion and anticipates non-GAAP gross margin will recover to approximately 62% for the full year, suggesting these pressures are expected to be transient.

Key Decisions for Investors

• Investors should weigh the strong revenue growth, raised full-year guidance, and significant market expansion in the type 2 diabetes segment against the current, albeit guided to be temporary, margin pressures.
• Monitor the non-GAAP gross margin in subsequent quarters to validate management's guidance for a second-half recovery; a failure to achieve the projected ~62% could indicate more persistent inflationary or supply chain issues.
• Key catalysts to watch for in H2 2025 include the commercial success of the newly approved G7 15 Day CGM, the revenue contribution from Stelo, and the material impact of expanded PBM coverage on new patient acquisition.
• The planned CEO succession for early 2026 is a longer-term factor to consider, though near-term execution appears strong with the current leadership team.